

Release of restricted securities from escrow

Melbourne, Australia, 18 July 2022: In accordance with ASX Listing Rule 3.10A, respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) advises that 85,536,074 securities in the Company (ASX Code: 4DXAA) (“Shares”) and 12,770,998 securities in the Company (ASX Code: 4DXAG) (“Options”), classified as restricted securities at the time that the Company was admitted to the official list of ASX, will be released from escrow on 8 August 2022. The Company will apply for quotation of the Shares, and the Options will remain unquoted.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Melanie Leydin
Company Secretary
companysecretary@4DMedical.com

Media

Julia Maguire
+ 61 (02) 8999 3699
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand lung function of patients with respiratory diseases.

Through its flagship patented XV Technology™, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical’s FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS™), which is the first and only modality that can dynamically quantify ventilation throughout the lungs. It additionally exposes the patient to lower levels of radiation relative to other diagnostic methods, a clear advantage when disease progression and therapeutic effectiveness need to be regularly monitored.

XV LVAS™ reports are prepared utilising 4DMedical’s Software as a Service delivery model using existing hospital imaging equipment or the company’s own revolutionary XV Scanner.

To learn more, please visit: www.4dmedical.com